Novartis on Monday said the U.S. Food and Drug Administration has granted breakthrough therapy status to the combination of Tafinlar and Mekinist to treat patients with BRAF V600-positive stage III melanoma following surgery.
ZURICH (Reuters) – Novartis on Monday said the U.S. Food and Drug Administration has granted breakthrough therapy status to the combination of Tafinlar and Mekinist to treat patients with BRAF V600-positive stage III melanoma following surgery.
&ldquo-There is a need for more effective treatment options for stage III melanoma patients at a high risk of recurrence following surgical resection,&rdquo- Samit Hirawat, head of global drug development at Novartis&rsquo- oncology unit, said in a release.
&ldquo-We thank the FDA for recognizing the scientific advancement Tafinlar and Mekinist may provide in this adjuvant setting.&rdquo-
0 comments
Share
